Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignace Vergote

Showing results (221-230 of 578) with videos related to

Pageof 58
Sort By:
Oncology Letters|June 8, 2017
Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancerFelicitas Mungenast, Stefanie Aust, Ignace Vergote, et al.
Breast Cancer Research and Treatment|May 4, 2005
Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-relatedHuei-Jean Huang, Patrick Neven, Maria Drijkoningen, et al.
Anti-Cancer Drugs|October 21, 2004
Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patientsLeilani Morales, Patrick Neven, Dirk Timmerman, et al.
Future Oncology (London, England)|November 4, 2017
A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancerKathleen N Moore, Lainie P Martin, David M O'Malley, et al.
European Journal of Cancer (Oxford, England : 1990)|July 23, 2017
Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancerKatrijn Michielsen, Raphaëla Dresen, Ragna Vanslembrouck, et al.
Current Problems in Cancer|June 4, 2023
Selinexor in patients with advanced and recurrent endometrial cancerGiorgio Bogani, Bradley J Monk, Robert L Coleman, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 24, 2012
Pelvic exenterations for gynecological malignancies: a study of 36 casesManpreet Kaur, Steven Joniau, André D'Hoore, et al.
The Lancet. Oncology|December 24, 2011
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled studyWalter H Gotlieb, Frederic Amant, Suresh Advani, et al.
European Journal of Anaesthesiology|June 19, 2015
Alizapride and ondansetron for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic gynaecological surgery: A double-blind, randomised, placebo-controlled noninferiority studyGeertrui Dewinter, An Teunkens, Kristien Vermeulen, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 12, 2018
The FIGO Stage IVA Versus IVB of Ovarian Cancer: Prognostic Value and Predictive Value for Neoadjuvant ChemotherapyParvin Tajik, Roelien van de Vrie, Mohammad H Zafarmand, et al.
Pageof 58

Showing results (221-230 of 578) with videos related to

Sort By:
Pageof 58
Oncology Letters|June 8, 2017
Clinical significance of the estrogen-modifying enzymes steroid sulfatase and estrogen sulfotransferase in epithelial ovarian cancerFelicitas Mungenast, Stefanie Aust, Ignace Vergote, et al.
Breast Cancer Research and Treatment|May 4, 2005
Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-relatedHuei-Jean Huang, Patrick Neven, Maria Drijkoningen, et al.
Anti-Cancer Drugs|October 21, 2004
Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patientsLeilani Morales, Patrick Neven, Dirk Timmerman, et al.
Future Oncology (London, England)|November 4, 2017
A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancerKathleen N Moore, Lainie P Martin, David M O'Malley, et al.
European Journal of Cancer (Oxford, England : 1990)|July 23, 2017
Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancerKatrijn Michielsen, Raphaëla Dresen, Ragna Vanslembrouck, et al.
Current Problems in Cancer|June 4, 2023
Selinexor in patients with advanced and recurrent endometrial cancerGiorgio Bogani, Bradley J Monk, Robert L Coleman, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 24, 2012
Pelvic exenterations for gynecological malignancies: a study of 36 casesManpreet Kaur, Steven Joniau, André D'Hoore, et al.
The Lancet. Oncology|December 24, 2011
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled studyWalter H Gotlieb, Frederic Amant, Suresh Advani, et al.
European Journal of Anaesthesiology|June 19, 2015
Alizapride and ondansetron for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic gynaecological surgery: A double-blind, randomised, placebo-controlled noninferiority studyGeertrui Dewinter, An Teunkens, Kristien Vermeulen, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 12, 2018
The FIGO Stage IVA Versus IVB of Ovarian Cancer: Prognostic Value and Predictive Value for Neoadjuvant ChemotherapyParvin Tajik, Roelien van de Vrie, Mohammad H Zafarmand, et al.
Pageof 58